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e thank Drs. Bartoletti and colleagues for their interest in our
tudy (1).
If one could operate in a world without risk and that is
nconstrained by costs, all incidental findings (IFs) could be
nvestigated. However, the investigation of IFs must be tempered
y the reality that benefits may be offset by risks and costs. In this
nblinded observational study, mortality was chosen as the primary
utcome measure because it is least influenced by subjectivity.
lthough we agree that when interventions prevent or delay death
he mortality in 2 groups will likely favor equivalence, it is also
mportant to recognize that survival benefits may also be attributed
o lead-time bias.
We also agree that a longer follow-up duration may have better
acilitated appreciation of differences in outcomes between com-
arison groups, and this limitation has been acknowledged. How-
ver, none of the indeterminate IFs became clinically significant.
he majority of the patients were followed up until a diagnosis was
ade or until no further follow-up was recommended (i.e., the IF
as deemed benign). Even if inferior outcomes were noted in IF
atients, further studies would be needed to explain whether the
ssociation is causal or serendipitous, given the benign disposition
f IFs.Most important is the readers’ observation that more studies are
eeded and that a randomized controlled trial of patients with
ndeterminate IF would be ideal and should be encouraged.
owever, one must accept that randomizing patients with IFs
ould be seen as unethical and may not be clinically feasible at
any centers. Thus, it is important that results such as ours be
sed to encourage discussion and to cast doubt on our current
linical practice, thus opening the opportunity for researchers to
ustify such randomized controlled trials.
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